[1]
Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nature genetics. 2014 Jun:46(6):607-12. doi: 10.1038/ng.2953. Epub 2014 Apr 20
[PubMed PMID: 24747642]
[2]
Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Annals of internal medicine. 1999 May 4:130(9):759-71
[PubMed PMID: 10357696]
Level 3 (low-level) evidence
[3]
Lam AK. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocrine pathology. 2017 Sep:28(3):213-227. doi: 10.1007/s12022-017-9484-5. Epub
[PubMed PMID: 28477311]
[4]
Rodgers SE, Evans DB, Lee JE, Perrier ND. Adrenocortical carcinoma. Surgical oncology clinics of North America. 2006 Jul:15(3):535-53
[PubMed PMID: 16882496]
[5]
Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine reviews. 2004 Apr:25(2):309-40
[PubMed PMID: 15082524]
[6]
Baudin E, Endocrine Tumor Board of Gustave Roussy. Adrenocortical carcinoma. Endocrinology and metabolism clinics of North America. 2015 Jun:44(2):411-34. doi: 10.1016/j.ecl.2015.03.001. Epub
[PubMed PMID: 26038209]
[7]
Sidhu S, Sywak M, Robinson B, Delbridge L. Adrenocortical cancer: recent clinical and molecular advances. Current opinion in oncology. 2004 Jan:16(1):13-8
[PubMed PMID: 14685087]
Level 3 (low-level) evidence
[8]
Macedo GS, Vieira IA, Vianna FSL, Alemar B, Giacomazzi J, Brandalize APC, Caleffi M, Volc SM, de Campos Reis Galvão H, Palmero EI, Achatz MI, Ashton-Prolla P. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers. Familial cancer. 2018 Apr:17(2):269-274. doi: 10.1007/s10689-017-0028-4. Epub
[PubMed PMID: 28756477]
[9]
Espiard S, Bertherat J. The genetics of adrenocortical tumors. Endocrinology and metabolism clinics of North America. 2015 Jun:44(2):311-34. doi: 10.1016/j.ecl.2015.02.004. Epub
[PubMed PMID: 26038203]
[10]
Assie G, Giordano TJ, Bertherat J. Gene expression profiling in adrenocortical neoplasia. Molecular and cellular endocrinology. 2012 Mar 31:351(1):111-7. doi: 10.1016/j.mce.2011.09.044. Epub 2011 Oct 25
[PubMed PMID: 22056416]
[11]
Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer research. 2005 Sep 1:65(17):7622-7
[PubMed PMID: 16140927]
[12]
Bonnet-Serrano F, Bertherat J. Genetics of tumors of the adrenal cortex. Endocrine-related cancer. 2018 Mar:25(3):R131-R152. doi: 10.1530/ERC-17-0361. Epub 2017 Dec 12
[PubMed PMID: 29233839]
[13]
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer cell. 2016 Aug 8:30(2):363. doi: 10.1016/j.ccell.2016.07.013. Epub 2016 Aug 8
[PubMed PMID: 27505681]
[14]
Nakamura Y, Yamazaki Y, Felizola SJ, Ise K, Morimoto R, Satoh F, Arai Y, Sasano H. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis. Endocrinology and metabolism clinics of North America. 2015 Jun:44(2):399-410. doi: 10.1016/j.ecl.2015.02.007. Epub
[PubMed PMID: 26038208]
[15]
Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. European journal of human genetics : EJHG. 2010 Jan:18(1):8-14. doi: 10.1038/ejhg.2009.106. Epub
[PubMed PMID: 19550435]
[16]
Barreau O, Assié G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, René-Corail F, Bertagna X, Dousset B, Hamzaoui N, Tissier F, de Reynies A, Bertherat J. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. The Journal of clinical endocrinology and metabolism. 2013 Jan:98(1):E174-84. doi: 10.1210/jc.2012-2993. Epub 2012 Oct 23
[PubMed PMID: 23093492]
[17]
Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, Åkerström G, Westin G, Lifton RP, Björklund P, Carling T. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes, chromosomes & cancer. 2012 Oct:51(10):949-60. doi: 10.1002/gcc.21978. Epub 2012 Jun 26
[PubMed PMID: 22733721]
[18]
Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS, Kebebew E. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. The Journal of clinical endocrinology and metabolism. 2012 Jun:97(6):E1004-13. doi: 10.1210/jc.2011-3298. Epub 2012 Apr 3
[PubMed PMID: 22472567]
[19]
Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, de la Villeon B, Faillot S, Hamzaoui N, Neou M, Perlemoine K, Rene-Corail F, Rodriguez S, Sibony M, Tissier F, Dousset B, Sbiera S, Ronchi C, Kroiss M, Korpershoek E, de Krijger R, Waldmann J, K D, Bartsch, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Sturm N, Luconi M, Mantero F, Mannelli M, Cohen R, Kerlan V, Touraine P, Barrande G, Groussin L, Bertagna X, Baudin E, Amar L, Beuschlein F, Clauser E, Coste J, Bertherat J. DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer. The Journal of clinical endocrinology and metabolism. 2017 Mar 1:102(3):923-932. doi: 10.1210/jc.2016-3205. Epub
[PubMed PMID: 27967600]
[20]
Chabre O, Libé R, Assie G, Barreau O, Bertherat J, Bertagna X, Feige JJ, Cherradi N. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocrine-related cancer. 2013 Aug:20(4):579-94. doi: 10.1530/ERC-13-0051. Epub 2013 Jul 5
[PubMed PMID: 23756429]
[21]
Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C, Lui WO. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine-related cancer. 2011 Oct:18(6):643-55. doi: 10.1530/ERC-11-0082. Epub 2011 Oct 27
[PubMed PMID: 21859927]
[22]
Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, Willscher E, Walz MK, Worm K, Schmid KW. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. Journal of clinical pathology. 2011 Jun:64(6):529-35. doi: 10.1136/jcp.2010.085621. Epub 2011 Apr 6
[PubMed PMID: 21471143]
[23]
Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 2011 Apr 15:117(8):1630-9. doi: 10.1002/cncr.25724. Epub 2010 Nov 8
[PubMed PMID: 21472710]
[24]
Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP, Lalli E. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer research. 2010 Jun 1:70(11):4666-75. doi: 10.1158/0008-5472.CAN-09-3970. Epub 2010 May 18
[PubMed PMID: 20484036]
[25]
Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008 Dec 1:113(11):3130-6. doi: 10.1002/cncr.23886. Epub
[PubMed PMID: 18973179]
[26]
Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996 Feb:119(2):161-70
[PubMed PMID: 8571201]
[27]
Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annals of surgical oncology. 1999 Dec:6(8):719-26
[PubMed PMID: 10622498]
[28]
Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000 Feb 15:88(4):711-36
[PubMed PMID: 10679640]
[29]
Audenet F, Méjean A, Chartier-Kastler E, Rouprêt M. Adrenal tumours are more predominant in females regardless of their histological subtype: a review. World journal of urology. 2013 Oct:31(5):1037-43. doi: 10.1007/s00345-012-1011-1. Epub 2013 Jan 9
[PubMed PMID: 23299088]
[30]
Hsing AW, Nam JM, Co Chien HT, McLaughlin JK, Fraumeni JF Jr. Risk factors for adrenal cancer: an exploratory study. International journal of cancer. 1996 Feb 8:65(4):432-6
[PubMed PMID: 8621222]
[31]
Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatric blood & cancer. 2005 Sep:45(3):265-73
[PubMed PMID: 15747338]
[32]
Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DG, Harris M, Kelsey AM, Birch JM. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. American journal of human genetics. 1999 Oct:65(4):995-1006
[PubMed PMID: 10486318]
[33]
Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute. 1994 Nov 16:86(22):1707-10
[PubMed PMID: 7966399]
[34]
Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M, Allolio B, Hahner S. TP53 germline mutations in adult patients with adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism. 2012 Mar:97(3):E476-85. doi: 10.1210/jc.2011-1982. Epub 2011 Dec 14
[PubMed PMID: 22170717]
[35]
Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism. 2013 Jan:98(1):E119-25. doi: 10.1210/jc.2012-2198. Epub 2012 Nov 21
[PubMed PMID: 23175693]
[36]
Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer research. 2010 Nov 1:70(21):8276-81. doi: 10.1158/0008-5472.CAN-10-2014. Epub 2010 Oct 19
[PubMed PMID: 20959480]
[37]
Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Nov 1:16(21):5133-41. doi: 10.1158/1078-0432.CCR-10-1497. Epub 2010 Oct 26
[PubMed PMID: 20978149]
[38]
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer cell. 2016 May 9:29(5):723-736. doi: 10.1016/j.ccell.2016.04.002. Epub
[PubMed PMID: 27165744]
[39]
Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. The Journal of clinical endocrinology and metabolism. 1997 Aug:82(8):2559-65
[PubMed PMID: 9253334]
[40]
Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA, Mendonca BB, Latronico AC. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. The Journal of clinical endocrinology and metabolism. 2008 Sep:93(9):3524-31. doi: 10.1210/jc.2008-0065. Epub 2008 Jul 8
[PubMed PMID: 18611974]
[41]
Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best practice & research. Clinical endocrinology & metabolism. 2009 Apr:23(2):261-71. doi: 10.1016/j.beem.2008.10.006. Epub
[PubMed PMID: 19500768]
[42]
Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. The Journal of clinical endocrinology and metabolism. 2010 Oct:95(10):E161-71. doi: 10.1210/jc.2010-0653. Epub 2010 Jul 21
[PubMed PMID: 20660055]
[43]
Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. The American journal of surgical pathology. 1984 Mar:8(3):163-9
[PubMed PMID: 6703192]
Level 2 (mid-level) evidence
[44]
Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond--histopathology for adrenocortical carcinoma. Hormones & cancer. 2011 Dec:2(6):333-40. doi: 10.1007/s12672-011-0088-0. Epub
[PubMed PMID: 21997290]
[45]
Zhang H, Bu H, Chen H, Wei B, Liu W, Guo J, Li F, Liao D, Tang Y, Zhang Z. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Applied immunohistochemistry & molecular morphology : AIMM. 2008 Jan:16(1):32-9
[PubMed PMID: 18091323]
[46]
Arola J, Liu J, Heikkilä P, Ilvesmäki V, Salmenkivi K, Voutilainen R, Kahri AI. Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm. The Journal of endocrinology. 2000 May:165(2):223-9
[PubMed PMID: 10810286]
[47]
Arola J, Liu J, Heikkilä P, Voutilainen R, Kahri A. Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors. Endocrine research. 1998 Aug-Nov:24(3-4):865-7
[PubMed PMID: 9888589]
[48]
Jorda M, De MB, Nadji M. Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas. Applied immunohistochemistry & molecular morphology : AIMM. 2002 Mar:10(1):67-70
[PubMed PMID: 11893039]
[49]
Schröder S, Padberg BC, Achilles E, Holl K, Dralle H, Klöppel G. Immunocytochemistry in adrenocortical tumours: a clinicomorphological study of 72 neoplasms. Virchows Archiv. A, Pathological anatomy and histopathology. 1992:420(1):65-70
[PubMed PMID: 1539453]
[50]
Ghorab Z, Jorda M, Ganjei P, Nadji M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Applied immunohistochemistry & molecular morphology : AIMM. 2003 Dec:11(4):330-3
[PubMed PMID: 14663359]
[51]
Duregon E, Volante M, Giorcelli J, Terzolo M, Lalli E, Papotti M. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Human pathology. 2013 May:44(5):822-8. doi: 10.1016/j.humpath.2012.07.025. Epub 2012 Nov 14
[PubMed PMID: 23158211]
Level 1 (high-level) evidence
[52]
Giordano TJ. The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. The American journal of surgical pathology. 2011 Apr:35(4):471-3. doi: 10.1097/PAS.0b013e31820bcf21. Epub
[PubMed PMID: 21383612]
[53]
Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. The American journal of surgical pathology. 1989 Mar:13(3):202-6
[PubMed PMID: 2919718]
[54]
Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sambaio GA, Cat I. Adrenocortical carcinoma in children: a study of 40 cases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Jan:8(1):67-74
[PubMed PMID: 2295912]
Level 3 (low-level) evidence
[55]
Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD. Adrenocortical carcinoma. Endocrine reviews. 2014 Apr:35(2):282-326. doi: 10.1210/er.2013-1029. Epub 2013 Dec 20
[PubMed PMID: 24423978]
[56]
Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical Carcinoma with Hypercortisolism. Endocrinology and metabolism clinics of North America. 2018 Jun:47(2):395-407. doi: 10.1016/j.ecl.2018.02.003. Epub 2018 Apr 9
[PubMed PMID: 29754640]
[57]
Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L, Carbone G, Casaccia M, Cavallaro A, Del Gaudio A, Dettori G, Di Giovanni V, Mazziotti A, Marrano D, Masenti E, Miccoli P, Mosca F, Mussa A, Petronio R, Piat G, Marazano L. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997 Dec:122(6):1212-8
[PubMed PMID: 9426440]
Level 3 (low-level) evidence
[58]
Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. The Journal of clinical endocrinology and metabolism. 2011 Dec:96(12):3775-84. doi: 10.1210/jc.2011-1565. Epub 2011 Sep 14
[PubMed PMID: 21917861]
[59]
Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV. Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. International braz j urol : official journal of the Brazilian Society of Urology. 2011 Jan-Feb:37(1):35-40;discussion 40-1
[PubMed PMID: 21385478]
[60]
Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, Brink JA, Baker ME, Federle MP, Foley WD, Francis IR, Herts BR, Israel GM, Krinsky G, Platt JF, Shuman WP, Taylor AJ. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. Journal of the American College of Radiology : JACR. 2010 Oct:7(10):754-73. doi: 10.1016/j.jacr.2010.06.013. Epub
[PubMed PMID: 20889105]
[61]
Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics : a review publication of the Radiological Society of North America, Inc. 2009 Sep-Oct:29(5):1333-51. doi: 10.1148/rg.295095027. Epub
[PubMed PMID: 19755599]
[62]
Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? Journal of the American College of Surgeons. 2006 Mar:202(3):423-30
[PubMed PMID: 16500246]
[63]
Lau J, Balk E, Rothberg M, Ioannidis JP, DeVine D, Chew P, Kupelnick B, Miller K. Management of clinically inapparent adrenal mass. Evidence report/technology assessment (Summary). 2002 Feb:(56):1-5
[PubMed PMID: 12945556]
[64]
Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Chatzellis E, Kaltsas G. Adrenal Incidentalomas. Endotext. 2000:():
[PubMed PMID: 25905250]
[65]
Egbert N, Elsayes KM, Azar S, Caoili EM. Computed tomography of adrenocortical carcinoma containing macroscopic fat. Cancer imaging : the official publication of the International Cancer Imaging Society. 2010 Nov 9:10(1):198-200. doi: 10.1102/1470-7330.2010.0029. Epub 2010 Nov 9
[PubMed PMID: 21067996]
[66]
Libé R. Clinical and molecular prognostic factors in adrenocortical carcinoma. Minerva endocrinologica. 2019 Mar:44(1):58-69. doi: 10.23736/S0391-1977.18.02900-0. Epub 2018 Sep 12
[PubMed PMID: 30221891]
[67]
Elsayes KM, Mukundan G, Narra VR, Lewis JS Jr, Shirkhoda A, Farooki A, Brown JJ. Adrenal masses: mr imaging features with pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc. 2004 Oct:24 Suppl 1():S73-86
[PubMed PMID: 15486251]
[68]
Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, Reznek RH. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR. American journal of roentgenology. 2011 Jun:196(6):W706-14. doi: 10.2214/AJR.10.5540. Epub
[PubMed PMID: 21606258]
[69]
Groussin L, Bonardel G, Silvéra S, Tissier F, Coste J, Abiven G, Libé R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X, Tenenbaum F. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. The Journal of clinical endocrinology and metabolism. 2009 May:94(5):1713-22. doi: 10.1210/jc.2008-2302. Epub 2009 Feb 3
[PubMed PMID: 19190108]
[70]
Sundin A. Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics. 2012:2(5):516-22. doi: 10.7150/thno.3613. Epub 2012 May 17
[PubMed PMID: 22737189]
[71]
Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. The Journal of clinical endocrinology and metabolism. 2006 Mar:91(3):920-5
[PubMed PMID: 16368753]
[72]
Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, Beuschlein F, Zink M, Lang K, Allolio B, Schirbel A. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. The Journal of clinical endocrinology and metabolism. 2008 Jun:93(6):2358-65. doi: 10.1210/jc.2008-0050. Epub 2008 Apr 8
[PubMed PMID: 18397978]
[73]
Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Current opinion in endocrinology, diabetes, and obesity. 2017 Jun:24(3):208-214. doi: 10.1097/MED.0000000000000332. Epub
[PubMed PMID: 28277340]
Level 3 (low-level) evidence
[74]
Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Frontiers in cell and developmental biology. 2015:3():45. doi: 10.3389/fcell.2015.00045. Epub 2015 Jul 3
[PubMed PMID: 26191527]
[75]
Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, Reimondo G, Pia A, Toscano V, Zini M, Borretta G, Papini E, Garofalo P, Allolio B, Dupas B, Mantero F, Tabarin A, Italian Association of Clinical Endocrinologists. AME position statement on adrenal incidentaloma. European journal of endocrinology. 2011 Jun:164(6):851-70. doi: 10.1530/EJE-10-1147. Epub 2011 Apr 6
[PubMed PMID: 21471169]
[76]
Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, Rowland C, Young WF Jr, van Heerden JA. Adrenocortical carcinoma: surgical progress or status quo? Archives of surgery (Chicago, Ill. : 1960). 2001 May:136(5):543-9
[PubMed PMID: 11343545]
[77]
Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. European journal of endocrinology. 2013 Dec:169(6):891-899. doi: 10.1530/EJE-13-0519. Epub 2013 Oct 23
[PubMed PMID: 24086089]
Level 2 (mid-level) evidence
[78]
Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, Behrend M, Allolio B, Fassnacht M, German ACC study group. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Annals of surgery. 2012 Feb:255(2):363-9. doi: 10.1097/SLA.0b013e3182367ac3. Epub
[PubMed PMID: 22143204]
[79]
Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE, Aloia TA. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surgical endoscopy. 2013 Nov:27(11):4026-32. doi: 10.1007/s00464-013-3034-0. Epub 2013 Jun 14
[PubMed PMID: 23765427]
[80]
Maurice MJ, Bream MJ, Kim SP, Abouassaly R. Surgical quality of minimally invasive adrenalectomy for adrenocortical carcinoma: a contemporary analysis using the National Cancer Database. BJU international. 2017 Mar:119(3):436-443. doi: 10.1111/bju.13618. Epub 2016 Sep 1
[PubMed PMID: 27488744]
Level 2 (mid-level) evidence
[81]
Lombardi CP, Raffaelli M, Boniardi M, De Toma G, Marzano LA, Miccoli P, Minni F, Morino M, Pelizzo MR, Pietrabissa A, Renda A, Valeri A, De Crea C, Bellantone R. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbeck's archives of surgery. 2012 Feb:397(2):201-7. doi: 10.1007/s00423-011-0866-8. Epub 2011 Nov 9
[PubMed PMID: 22069043]
[82]
Dy BM, Wise KB, Richards ML, Young WF Jr, Grant CS, Bible KC, Rosedahl J, Harmsen WS, Farley DR, Thompson GB. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013 Dec:154(6):1292-9; discussion 1299. doi: 10.1016/j.surg.2013.06.033. Epub
[PubMed PMID: 24238048]
[83]
Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T, Schrump DS. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. The Annals of thoracic surgery. 2011 Oct:92(4):1195-200. doi: 10.1016/j.athoracsur.2011.05.013. Epub
[PubMed PMID: 21958764]
[84]
op den Winkel J, Pfannschmidt J, Muley T, Grünewald C, Dienemann H, Fassnacht M, Allolio B. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. The Annals of thoracic surgery. 2011 Dec:92(6):1965-70. doi: 10.1016/j.athoracsur.2011.07.088. Epub 2011 Oct 13
[PubMed PMID: 22000277]
[85]
Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I. Operative management for recurrent and metastatic adrenocortical carcinoma. Journal of surgical oncology. 2012 Jun 1:105(7):709-13. doi: 10.1002/jso.23015. Epub 2011 Dec 20
[PubMed PMID: 22189845]
[86]
Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism. 2006 Nov:91(11):4501-4
[PubMed PMID: 16895957]
[87]
Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS, Worden F, Hammer GD, Jolly S. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. International journal of radiation oncology, biology, physics. 2015 Jun 1:92(2):252-9. doi: 10.1016/j.ijrobp.2015.01.007. Epub 2015 Mar 5
[PubMed PMID: 25754631]
[88]
Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, Perrier ND, Lee JE, Vassilopoulou-Sellin R. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism. 2013 Jan:98(1):192-7. doi: 10.1210/jc.2012-2367. Epub 2012 Nov 12
[PubMed PMID: 23150683]
Level 2 (mid-level) evidence
[89]
Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T, Kaushal A. Role of radiotherapy in adrenocortical carcinoma. Cancer journal (Sudbury, Mass.). 2013 Jul-Aug:19(4):288-94. doi: 10.1097/PPO.0b013e31829e3221. Epub
[PubMed PMID: 23867507]
[90]
Pivonello R, De Leo M, Cozzolino A, Colao A. The Treatment of Cushing's Disease. Endocrine reviews. 2015 Aug:36(4):385-486. doi: 10.1210/er.2013-1048. Epub 2015 Jun 11
[PubMed PMID: 26067718]
[91]
Rao SN, Habra MA. 5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications. Hormones & cancer. 2016 Feb:7(1):17-23. doi: 10.1007/s12672-015-0247-9. Epub 2015 Dec 10
[PubMed PMID: 26660146]
[92]
Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007 Dec:142(6):867-75; discussion 867-75
[PubMed PMID: 18063070]
[93]
Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD, Wotring LL. Adrenal proteins bound by a reactive intermediate of mitotane. Cancer chemotherapy and pharmacology. 1997:39(6):537-40
[PubMed PMID: 9118466]
[94]
Lindhe O, Skogseid B, Brandt I. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. The Journal of clinical endocrinology and metabolism. 2002 Mar:87(3):1319-26
[PubMed PMID: 11889204]
[95]
Schteingart DE, Sinsheimer JE, Counsell RE, Abrams GD, McClellan N, Djanegara T, Hines J, Ruangwises N, Benitez R, Wotring LL. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer chemotherapy and pharmacology. 1993:31(6):459-66
[PubMed PMID: 8453685]
[96]
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. The New England journal of medicine. 2007 Jun 7:356(23):2372-80
[PubMed PMID: 17554118]
[97]
Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons. 2016 Apr:222(4):480-90. doi: 10.1016/j.jamcollsurg.2015.12.013. Epub 2015 Dec 21
[PubMed PMID: 26775162]
[98]
Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Annals of surgical oncology. 2010 Jan:17(1):263-70. doi: 10.1245/s10434-009-0716-x. Epub 2009 Oct 23
[PubMed PMID: 19851811]
[99]
Lindhe O, Skogseid B. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2010 Sep:42(10):725-30. doi: 10.1055/s-0030-1261923. Epub 2010 Jul 27
[PubMed PMID: 20665429]
[100]
Miller BS, Else T, AACE Adrenal Scientific Committee. PERSONALIZED CARE OF PATIENTS WITH ADRENOCORTICAL CARCINOMA: A COMPREHENSIVE APPROACH. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2017 Jun:23(6):705-715. doi: 10.4158/EP161719.RA. Epub
[PubMed PMID: 28614035]
[101]
Terzolo M, Ardito A, Zaggia B, Laino F, Germano A, De Francia S, Daffara F, Berruti A. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine. 2012 Dec:42(3):521-5. doi: 10.1007/s12020-012-9719-7. Epub 2012 Jun 17
[PubMed PMID: 22706605]
[102]
De Francia S, Ardito A, Daffara F, Zaggia B, Germano A, Berruti A, Di Carlo F. Mitotane treatment for adrenocortical carcinoma: an overview. Minerva endocrinologica. 2012 Mar:37(1):9-23
[PubMed PMID: 22382612]
Level 3 (low-level) evidence
[103]
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B, FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. The New England journal of medicine. 2012 Jun 7:366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2
[PubMed PMID: 22551107]
[104]
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-related cancer. 2010 Jun:17(2):445-53. doi: 10.1677/ERC-09-0281. Epub 2010 Apr 21
[PubMed PMID: 20410174]
[105]
Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World journal of surgery. 2014 Jun:38(6):1318-27. doi: 10.1007/s00268-014-2484-4. Epub
[PubMed PMID: 24615603]
[106]
Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism. 2009 Jan:94(1):204-12. doi: 10.1210/jc.2008-1456. Epub 2008 Oct 14
[PubMed PMID: 18854392]
[107]
Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Hormones & cancer. 2014 Aug:5(4):232-9. doi: 10.1007/s12672-014-0182-1. Epub 2014 May 22
[PubMed PMID: 24849545]
[108]
Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. The Lancet. Oncology. 2015 Apr:16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18
[PubMed PMID: 25795408]
Level 1 (high-level) evidence
[109]
Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. British journal of cancer. 2013 Mar 5:108(4):826-30. doi: 10.1038/bjc.2013.46. Epub 2013 Feb 14
[PubMed PMID: 23412108]
[110]
Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best practice & research. Clinical endocrinology & metabolism. 2009 Apr:23(2):273-89. doi: 10.1016/j.beem.2008.10.008. Epub
[PubMed PMID: 19500769]
[111]
Phan AT. Adrenal cortical carcinoma--review of current knowledge and treatment practices. Hematology/oncology clinics of North America. 2007 Jun:21(3):489-507; viii-ix
[PubMed PMID: 17548036]
[112]
Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World journal of surgery. 2001 Jul:25(7):891-7
[PubMed PMID: 11572030]
[113]
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B, German Adrenocortical Carcinoma Registry Group, European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009 Jan 15:115(2):243-50. doi: 10.1002/cncr.24030. Epub
[PubMed PMID: 19025987]
[114]
Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism. 2013 Dec:98(12):4551-64. doi: 10.1210/jc.2013-3020. Epub 2013 Sep 30
[PubMed PMID: 24081734]
[115]
Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, Sidhu SB. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Dec 15:15(24):7684-7692
[PubMed PMID: 19996210]
[116]
Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. The Journal of clinical endocrinology and metabolism. 2006 Jun:91(6):2027-37
[PubMed PMID: 16551738]
[117]
Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England journal of medicine. 1990 Apr 26:322(17):1195-201
[PubMed PMID: 2325710]